...
首页> 外文期刊>BMC Cancer >DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors
【24h】

DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors

机译:与原发性肿瘤比较的转移性尿路上皮癌的DNA拷贝数分析

获取原文
           

摘要

Background To date, there have been no reports characterizing the genome-wide somatic DNA chromosomal copy-number alteration landscape in metastatic urothelial carcinoma. We sought to characterize the DNA copy-number profile in a cohort of metastatic samples and compare them to a cohort of primary urothelial carcinoma samples in order to identify changes that are associated with progression from primary to metastatic disease. Methods Using molecular inversion probe array analysis we compared genome-wide chromosomal copy-number alterations between 30 metastatic and 29 primary UC samples. Whole transcriptome RNA-Seq analysis was also performed in primary and matched metastatic samples which was available for 9 patients. Results Based on a focused analysis of 32 genes in which alterations may be clinically actionable, there were significantly more amplifications/deletions in metastases (8.6% vs 4.5%, p?Conclusions The discordance in alterations between primary and metastatic tissue may be of clinical relevance in the era of genomically directed precision cancer medicine.
机译:背景技术迄今为止,尚无报道转移性尿路上皮癌中全基因组体细胞DNA染色体拷贝数变化情况的报道。我们试图表征一组转移样品中的DNA拷贝数特征,并将其与原发性尿路上皮癌样品进行比较,以鉴定与原发性至转移性疾病进展相关的变化。方法使用分子倒置探针阵列分析,我们比较了30个转移性和29个主要UC样本之间的全基因组染色体拷贝数变化。在主要和匹配的转移性样品中也进行了全转录组RNA-Seq分析,可用于9名患者。结果基于对32种基因的集中分析,其中改变可能在临床上是可行的,转移中的扩增/缺失明显更多(8.6%vs 4.5%,p?)。结论原发和转移组织之间改变的不一致可能与临床有关在基因组学指导的精准癌症医学时代。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号